Skip to content
OpenCapital
Get started

Tango Therapeutics TNGX Accrued Research And Development Costs Current

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept tngx:AccruedResearchAndDevelopmentCostsCurrent.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Tango Therapeutics's accrued research and development costs current?
Tango Therapeutics (TNGX) reported accrued research and development costs current of $4.27M in Q1 2026.
How has Tango Therapeutics's accrued research and development costs current changed year-over-year?
Tango Therapeutics's accrued research and development costs current decreased by 18.1% year-over-year, from $5.22M to $4.27M.
What is the long-term trend for Tango Therapeutics's accrued research and development costs current?
Over 5 years (2020 to 2025), Tango Therapeutics's accrued research and development costs current has grown at a 22.5% compound annual growth rate (CAGR), from $2.7M to $7.42M.